The Economic Benefits of Pharmacogenomics (PGx) Testing: Predicting Cost Savings in Healthcare

The Economic Benefits of Pharmacogenomics (PGx) Testing: Predicting Cost Savings in Healthcare

In the era of personalised medicine, pharmacogenomics (PGx) testing is gaining traction as a powerful tool for tailoring drug therapies to individual genetic profiles. While the primary focus of PGx testing is to improve patient outcomes by optimising drug efficacy and minimising adverse drug reactions (ADRs), there is growing evidence that it can also lead to significant cost savings in healthcare. This blog explores the economic benefits of PGx testing, drawing on several key studies that predict substantial savings through its implementation.

 

How PGx Testing Saves Costs

Pharmacogenomics testing works by identifying genetic variations that affect how a patient metabolises or responds to certain medications. By understanding these variations, healthcare providers can select the most appropriate drug and dosage for each patient, thereby reducing the likelihood of ineffective treatments and harmful side effects. But beyond improving clinical outcomes, PGx testing offers economic advantages by reducing the overall cost of care.

 

1. Economic Impact in Antidepressant Treatment

One of the most compelling cases for PGx testing comes from its application in the treatment of depression. Depression is often treated with a trial-and-error approach, where patients may need to try multiple antidepressants before finding one that works for them. This process can be lengthy, costly, and emotionally taxing.

 A study published in The Journal of Managed Care & Specialty Pharmacy in 2018 evaluated the cost-effectiveness of PGx testing in patients undergoing antidepressant treatment. The study found that PGx testing could lead to an estimated cost saving of approximately $2,000 per patient over the course of one year. These savings were attributed to faster identification of effective medications, reducing the number of consultation visits, hospitalizations, and other associated healthcare costs. By helping patients achieve remission sooner, PGx testing not only improves quality of life but also reduces the economic burden on the healthcare system.

 

2. Cost-Effectiveness in Cardiovascular Disease

Cardiovascular diseases are among the leading causes of morbidity and mortality worldwide, and medications like clopidogrel are commonly prescribed to manage these conditions. However, genetic variations, particularly in the CYP2C19 gene, can significantly affect how patients metabolise clopidogrel, impacting its efficacy.

 A study published in Pharmacoeconomics in 2014 explored the cost-effectiveness of PGx testing in patients with cardiovascular disease. The study concluded that PGx testing could prevent adverse cardiovascular events, such as heart attacks and strokes, in patients with specific genetic variations. By guiding therapy with PGx insights, healthcare providers can avoid costly complications, resulting in substantial cost savings. The study highlighted that PGx-guided therapy is particularly beneficial in preventing serious and expensive health events, thus underscoring the economic value of incorporating genetic testing into routine care for cardiovascular patients.

 

3. Reduction in Hospitalisations

Hospitalisations are a major driver of healthcare costs, especially when they result from adverse drug reactions or ineffective treatments. PGx testing can play a significant role in reducing these hospitalisations by ensuring that patients receive the right medication from the outset.

 A study published in the American Journal of Medicine in 2017 analysed the impact of PGx testing on hospitalisation rates. The study found that patients who underwent PGx-guided treatment experienced fewer hospitalizations and emergency room visits compared to those who did not receive PGx testing. This reduction in hospital admissions led to significant cost savings per patient, providing strong evidence for the broader adoption of PGx testing as a cost-saving measure in clinical practice.

 

4. Long-Term Savings in Polypharmacy

Polypharmacy, the use of multiple medications by a single patient, is common among older adults and those with chronic conditions. This increases the risk of drug-drug interactions and adverse effects, which can be costly to manage.

 A study published in Clinical Therapeutics in 2020 examined the long-term cost implications of PGx testing in patients on multiple medications. The study suggested that PGx testing could lead to substantial savings over time by optimising medication regimens, reducing adverse drug reactions, and improving patient adherence to prescribed therapies. These savings were particularly pronounced in older adults, who are at higher risk for complications due to polypharmacy. By personalising treatment plans, PGx testing not only improves patient outcomes but also reduces the long-term costs associated with managing complex medication regimens.

 

The Future of Cost-Effective Healthcare

 The studies highlighted in this blog provide compelling evidence that PGx testing is not just a tool for improving patient care but also a strategy for reducing healthcare costs. By facilitating the selection of the most effective and safe medications for each patient, PGx testing helps to minimise the trial-and-error approach, reduce hospitalisations, and prevent costly adverse drug reactions. As healthcare systems around the world continue to grapple with rising costs, the implementation of PGx testing offers a promising path toward more cost-effective and efficient care. The economic benefits, coupled with the potential for improved patient outcomes, make a strong case for the wider adoption of PGx testing in clinical practice. As we move further into the era of personalised medicine, the integration of pharmacogenomics into routine care has the potential to revolutionise healthcare delivery, ensuring that treatments are not only tailored to the individual but also cost-effective on a broader scale.

At AttoDiagnostics , we believe that integrating pharmacogenomics into routine healthcare can revolutionise patient outcomes and cost-efficiency. For more details on our PGx solutions, feel free to Get a Quote or even Request a PGx demo here. 

 

Request a PGx Demo